Articles producció científicaInfermeria

The Predictive Potential of C-Peptide in Differentiating Type 1 Diabetes From Type 2 Diabetes in an Outpatient Population in Abu Dhabi

  • Dades identificatives

    Identificador:  imarina:9382515
    Autors:  Iqbal, S; Abu Jayyab, A; Alrashdi, AM; Shujauddin, S; Clua-Espuny, JL; Reverté-Villarroya, S
    Resum:
    Purpose: We aimed to investigate the predictive potential of plasma connecting peptide (C-peptide) in differentiating type 1 diabetes (T1D) from type 2 diabetes (T2D) and to inform evidence-based diabetes classification criteria. Methods: A retrospective review was performed of all the patients with diabetes visiting an outpatient diabetology, endocrinology, general practice and family medicine tertiary health care center between January 2016 and December 2021. Findings: Two hundred twelve individuals with diabetes were included, 85 (44.8%) with T1D and 127 (55.2%) with T2D. Mean (SD) age at diagnosis was 35.9 (15.1) years, and 112 (52.8%) men. Median (interquartile range [IQR]) duration of diabetes was 3.8 (3.0-4.5) years (T1D, 3.9 [3.5-4.6]; T2D, 3.4 [2.4-4.4]; P = 0.001). Body mass index was < 18.5 kg/m2 2 in 5 (2.5%) individuals (T1D, 5; T2D, none), 18.5 to < 25 kg/m2 2 in 57 (28.5%) (T1D, 32; T2D, 25), 25 to < 30 kg/m2 2 in 58 (29%) (T1D, 28; T2D, 30), and > 30 kg/m2 2 in 80 (40.0%) (T1D, 20; T2D, 60). Median (IQR) glycosylated hemoglobin was 7.4% (6.7%-8.5%) (T1D, 8.3% [7.2%-9.9%]; T2D, 7% [6.3%- 7.6%]; P = 0.0001). Median (IQR) C-peptide concentration was 0.59 nmol/L (0.01-1.14 nmol/L) (T1D, 0.01 nmol/L [0.003-0.05 nmol/L]; T2D, 1.03 nmol/L [0.70-1.44 nmol/L]; P = 0.0001). C-peptide concentration of
  • Altres:

    Enllaç font original: https://www.sciencedirect.com/science/article/pii/S0149291824002030
    Referència de l'ítem segons les normes APA: Iqbal, S; Abu Jayyab, A; Alrashdi, AM; Shujauddin, S; Clua-Espuny, JL; Reverté-Villarroya, S (2024). The Predictive Potential of C-Peptide in Differentiating Type 1 Diabetes From Type 2 Diabetes in an Outpatient Population in Abu Dhabi. CLINICAL THERAPEUTICS, 46(9), 696-701. DOI: 10.1016/j.clinthera.2024.07.002
    Referència a l'article segons font original: CLINICAL THERAPEUTICS. 46 (9): 696-701
    DOI de l'article: 10.1016/j.clinthera.2024.07.002
    Any de publicació de la revista: 2024-09-12
    Entitat: Universitat Rovira i Virgili
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Data d'alta del registre: 2026-05-09
    Autor/s de la URV: Reverté Villarroya, Silvia / Sajid, Iqbal
    Departament: Infermeria
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Tipus de publicació: Journal Publications
    Autor segons l'article: Iqbal, S; Abu Jayyab, A; Alrashdi, AM; Shujauddin, S; Clua-Espuny, JL; Reverté-Villarroya, S
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Àrees temàtiques: Pharmacology (medical), Pharmacology & pharmacy, Pharmacology, Medicina ii, General medicine, Ciências biológicas i
    Adreça de correu electrònic de l'autor: iqbal.sajid@estudiants.urv.cat, silvia.reverte@urv.cat, silvia.reverte@urv.cat
  • Paraules clau:

    Β-cell function
    Type 2 diabetes
    Type 2 diabete
    Type 1 diabetes
    Retrospective studies
    Prevalence
    Predictive value of tests
    Predictive ability of c-peptide
    Pilot
    Outpatients
    Middle aged
    Mellitus
    Male
    Humans
    Help
    Glycated hemoglobin
    Female
    Diagnosis
    differential
    Diabetes mellitus
    type 2
    type 1
    Classification
    Children
    C-peptide
    Biomarkers
    Beta-cell function
    Ag
    Adults
    Adult
    Pharmacology
    Pharmacology & Pharmacy
    Pharmacology (Medical)
    Medicina ii
    General medicine
    Ciências biológicas i
  • Documents:

  • Cerca a google

    Search to google scholar